All In Biotech

Drug Trial Radar · NCT06402838

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers Following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

256

Actual

Start

May 2, 2024

Primary completion

Nov 19, 2026

Study completion Nov 19, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain. People who take part in this clinical trial (participants) will be given RO7269162 OR placebo for up to about 1 and a half years. The clinical trial team will see them every 3 weeks in the first 3 months and then every 6 weeks until the end of the trial. These hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The total time of participation in the clinical trial will be 90 weeks.

Conditions

  • Alzheimer's Disease

Interventions

  • RO7269162Drug

    Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.

  • PlaceboDrug

    Participants will receive daily doses of placebo for up to 72 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: up to week 72
  2. Change from baseline in brain amyloid load, as measured by amyloid positron emission tomography ( PET) scanTime frame: Baseline to Week 72

Locations

45 sites in 9 countries. Site status is shown where the registry gives one.

  • Centro de Investigación Clínica UC-CICUC

    Santiago, Chile

  • Hospital Clinico Univ de Chile

    Santiago, Chile

  • Aarhus Universitetshospital Skejby

    Aarhus N, Denmark

  • Rigshospitalet, Hukommelsesklinikken

    Koebenhavn Oe, Denmark

  • Groupement Hospitalier Est - Hôpital Neurologique

    Bron, France

  • Hopital B Roger Salengro

    Lille, France

  • Hôpital de la Timone

    Marseille, France

  • Hôpital Lariboisière

    Paris, France

  • CHU de Rouen Hopital

    Rouen, France

  • Hop Guillaume Et Rene Laennec

    Saint-Herblain, France

  • Hôpital Robertsau

    Strasbourg, France

  • Gerontopole

    Toulouse, France

  • Ambulates Gesundheitszentrum der Charité GmbH

    Berlin, Germany

  • TUM Klinikum rechts der Isar;Ambulanz für neurokognitive Erkrankungen

    München, Germany

  • Ospedale Cardinale Panico

    Tricase (LE), Apulia, Italy

  • Umberto I Policlinico di Roma-Università di Roma La Sapienza

    Rome, Lazio, Italy

  • IRCCS Ospedale San Raffaele

    Milan, Lombardy, Italy

  • Fondazione Istituto Neurologico Mondino IRCCS

    Pavia, Lombardy, Italy

  • ProNeuro Centrum Medyczne

    ?ory, Poland

  • Podlaskie Centrum Psychogeriatrii

    Bia?ystok, Poland

  • NZOZ Vitamed

    Bydgoszcz, Poland

  • NEURO-CARE Sp. z o.o. Sp. Komandytowa

    Katowice, Poland

  • Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Senior Sp. Z O.O. Poradnia Psychogeriatryczna

    Sopot, Poland

  • EUROMEDIS Sp z o o

    Szczecin, Poland

  • ETG Neuroscience Sp. z o.o.

    Warsaw, Poland

  • NZOZ WCA

    Wroc?aw, Poland

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Fundacio ACE

    Barcelona, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Victoria Eugenia

    Seville, Spain

  • Hospital Virgen del Rocío

    Seville, Spain

  • Hospital Universitario Dr. Peset

    Valencia, Spain

  • Hospital Universitario la Fe

    Valencia, Spain

  • Hospital General De Catalunya

    Sant Cugat del Vallès, Barcelona, Spain

  • Policlínica Guipuzcoa

    Donostia / San Sebastian, Guipuzcoa, Spain

  • Hospital Quiron de Madrid

    Pozuelo de Alarcón, Madrid, Spain

  • Complejo Asistencial Universitario de Salamanca

    Salamaca, Salamanca, Spain

  • Surrey and Borders NHS Foundation Trust

    Chertsey, United Kingdom

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.